Susanne Saussele (Susanne Saußele)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 52

Top Venues

Leukemia

Cancers

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Annals of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia 38 (4) (2024)
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia 38 (8) (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Francois-Xavier Mahon, Markus Pfirrmann, Stephanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Almeida, Jiří Mayer, Henrik Hjorth-Hansen, Jeroen J W M Janssen, Mohamed El Missiry, Joaquin Martinez Lopez, Hanne Vestergaard, Hans Ehrencrona, Katerina Machová Poláková, Ulla Olsson-Strömberg, Gert Ossenkoppele, Marc G Berger, Gabriel Etienne, Jolanta Dengler, Tim Henrik Brümmendorf, Andreas Burchert, Delphine Rea, Philippe Rousselot, Franck E Nicolini, Wolf-Karsten Hofmann, Johan Richter, Susanne Saussele, null null, null null
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (16) (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia 38 (4) (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia 38 (4) (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia 38 (4) (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia (2024)
Francois-Xavier Mahon, Markus Pfirrmann, Stephanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Antonio Almeida, Jiří Mayer, Henrik Hjorth-Hansen, Jeroen J W M Janssen, Mohamed El Missiry, Joaquin Martinez Lopez, Hanne Vestergaard, Hans Ehrencrona, Katerina Machová Poláková, Ulla Olsson-Strömberg, Gert Ossenkoppele, Marc G Berger, Gabriel Etienne, Jolanta Dengler, Tim Henrik Brümmendorf, Andreas Burchert, Delphine Rea, Philippe Rousselot, Franck E Nicolini, Wolf-Karsten Hofmann, Johan Richter, Susanne Saussele, null null
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia (2024)
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elżbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan W Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia 38 (5) (2024)
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Franck E Nicolini, Jiri Mayer, Daniela Zackova, Jeroen J W M Janssen, Panayiotis Panayiotidis, Hanne Vestergaard, Perttu Koskenvesa, Antonio Almeida, Henrik Hjorth-Hansen, Joaquin Martinez-Lopez, Ulla Olsson-Strömberg, Andreas Hochhaus, Marc G Berger, Gabriel Etienne, Hana Klamova, Edgar Faber, Philippe Rousselot, Markus Pfirrmann, Susanne Saussele
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial. Leukemia 38 (8) (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia 38 (4) (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia (2024)
Hjalmar Flygt, Stina Söderlund, Johan Richter, Susanne Saussele, Perttu Koskenvesa, Leif Stenke, Mohamed El Missiry, Andreja Dimitrijevic, Jesper Stentoft, Waleed Majeed, Lydia Roy, Dominik Wolf, Arta Dreimane, Bjørn Tore Gjertsen, Tobias Gedde-Dahl, Erik Ahlstrand, Berit Markevärn, Henrik Hjorth-Hansen, Jeroen Janssen, Ulla Olsson-Strömberg
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia (2024)
Markus Pfirrmann, Susanne Saussele, François-Xavier Mahon, Johan Richter
How to interpret the EURO-SKI study and its treatment-free remission outcome. Reply to R.P. Gale and J. Chen. Leukemia 38 (2) (2024)
Eva Christiani, Nicole Naumann, Christel Weiss, Birgit Spiess, Helga Kleiner, Alice Fabarius, Wolf-Karsten Hofmann, Susanne Saussele, Wolfgang Seifarth
Gene Expression Pattern of ESPL1 , PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML. Cancers 15 (9) (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Michael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, Susanne Saussele
Survival with chronic myeloid leukaemia after failing milestones. Leukemia (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Birgit Spiess, Helga Kleiner, Irina Tarnopolscaia, Nicole Naumann, Alice Fabarius, Wolf-Karsten Hofmann, Susanne Saussele, Wolfgang Seifarth
Reverse Transcription Can Critically Impact the Diagnostic Outcome of BCR::ABL1 Quantitative Real-Time RT-PCR. Cancers 15 (15) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Eva Christiani, Nicole Naumann, Christel Weiss, Birgit Spiess, Helga Kleiner, Alice Fabarius, Wolf-Karsten Hofmann, Susanne Saussele, Wolfgang Seifarth
Gene Expression Pattern of ESPL1 , PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML. Cancers 15 (9) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37 (3) (2023)
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, Yosuke Minami, Jorge E Cortes, Timothy P Hughes, Jane F Apperley, Elza Lomaia, Sergey Voloshin, Anna G Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koiji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, J Valentín García-Gutiérrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Michael J Mauro
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Nikola Curik, Alice Fabarius, Hana Klamova, Birgit Spiess, Cornelius F Waller, Tim Henrik Brümmendorf, Jolanta Dengler, Volker Kunzmann, Andreas Burchert, Petra Belohlavkova, Mohamed El Missiry, Edgar Faber, Jiří Mayer, Daniela Zackova, Panayiotis Panayiotidis, Johan Richter, Henrik Hjorth-Hansen, Magdalena Kamińska, Magdalena Płonka, Elżbieta Szczepanek, Monika Szarejko, Grażyna Bober, Iwona Hus, Olga Grzybowska-Izydorczyk, Ewa Wasilewska, Edyta Paczkowska, Joanna Niesiobędzka-Krężel, Krzysztof Giannopoulos, Francois X Mahon, Tomasz Sacha, Susanne Saussele, Markus Pfirrmann
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib. Leukemia 38 (2) (2023)
Jil Rotterdam, Margot Thiaucourt, Christel Weiss, Juliana Schwaab, Andreas Reiter, Sebastian Kreil, Laurenz Steiner, Sebastian Fenchel, Henning D Popp, Wolf-Karsten Hofmann, Karin Bonatz, Catharina Gerhards, Michael Neumaier, Stefan A Klein, Sonika Rao, Mohamad Jawhar, Susanne Saussele
Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases. Annals of hematology 101 (8) (2022)
Rüdiger Hehlmann, Michael Lauseker, Astghik Voskanyan, Alice Fabarius, Claudia Haferlach, Andreas Hochhaus, Susanne Saussele
Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia 36 (10) (2022)
Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim Henrik Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia 36 (9) (2022)
Helen E White, Matthew Salmon, Francesco Albano, Christina Søs Auður Andersen, Stefan Balabanov, Gueorgui Balatzenko, Gisela Barbany, Jean-Michel Cayuela, Nuno Cerveira, Pascale Cochaux, Dolors Colomer, Daniel Coriu, Joana Diamond, Christian Dietz, Stephanie Dulucq, Marie Engvall, Georg N Franke, Egle Gineikiene-Valentine, Michał Gniot, María Teresa Gómez-Casares, Enrico Gottardi, Chloe Hayden, Sandrine Hayette, Andreas Hedblom, Anca Ilea, Barbara Izzo, Antonio Jiménez-Velasco, Tomas Jurcek, Veli Kairisto, Stephen E Langabeer, Thomas Lion, Nora Meggyesi, Semir Mešanović, Luboslav Mihok, Gerlinde Mitterbauer-Hohendanner, Sylvia Moeckel, Nicole Naumann, Olivier Nibourel, Elisabeth Oppliger Leibundgut, Panayiotis Panayiotidis, Helena Podgornik, Christiane Pott, Inmaculada Rapado, Susan J Rose, Vivien Schäfer, Tasoula Touloumenidou, Christopher Veigaard, Bianca Venniker-Punt, Claudia Venturi, Paolo Vigneri, Ingvild Vorkinn, Elizabeth Wilkinson, Renata Zadro, Magdalena Zawada, Hana Zizkova, Martin C Müller, Susanne Saussele, Thomas Ernst, Katerina Machova Polakova, Andreas Hochhaus, Nicholas C P Cross
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia 36 (7) (2022)
Delphine Rea, Michael J Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Andre Neder Ramires Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem Chaudhri, Koiji Sasaki, Lynette Chee, J Valentín García-Gutiérrez, Jorge E Cortes, Paola Aimone, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Andreas Hochhaus
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138 (21) (2021)
Jerald P Radich, Andreas Hochhaus, Tamas Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez Casares, J Valentín García-Gutiérrez, Eibhlin Conneally, Philipp D le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saussele, Francis J Giles, David Morrall Ross, Paola Aimone, Sai Li, Ksenia Titorenko, Giuseppe Saglio
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia 35 (5) (2021)
Johan Richter, Anna Lübking, Stina Söderlund, Kourosh Lotfi, Berit Markevärn, Anders Själander, Leif Stenke, Stefan Deneberg, Erik Ahlstrand, Kristina Myhr-Eriksson, Panayiotis Panayiotidis, Tobias Gedde-Dahl, Daniela Žáčková, Jiří Mayer, Ulla Olsson-Strömberg, Francois-Xavier Mahon, Susanne Saussele, Henrik Hjorth-Hansen, Perttu Koskenvesa
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI. Leukemia 35 (8) (2021)

Susanne Saussele.css-eqlu8i{font-size:small;padding-left:4px;} (Susanne Saußele)

Publication Activity (10 Years)

Top Topics

Top Venues

Susanne Saussele (Susanne Saußele)